(rac)-ZK-304709 is a first-in-class, orally active, multi-targeted tumor growth inhibitor that suppresses the proliferation and colony formation of neuroendocrine tumor (NET) cells in a dose-dependent manner; it induces G2 cell cycle arrest and apoptosis in NET cells, downregulates the expression of MCL1, survivin, and HIF1α, and significantly inhibits primary tumor growth and tumor-induced angiogenesis, demonstrating its potential as a therapeutic agent for NET.